Stock Events

Mesoblast 

$0.71
3
-$0.01-1.22% Friday 12:04

Statistics

Day High
0.84
Day Low
0.84
52W High
1
52W Low
0.1
Volume
100
Avg. Volume
103,052
Mkt Cap
815.23M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Earnings

28AugConfirmed
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Next
-0.66
-0.44
-0.22
0
Expected EPS
-0.0353
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MEOBF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biolife Solutions
BLFS
Mkt Cap935.2M
BioLife Solutions provides bioproduction tools and services, including cell and gene therapy solutions, which are essential for companies like Mesoblast, making them a competitor in the supply chain.
Fate Therapeutics
FATE
Mkt Cap418.9M
Fate Therapeutics is focused on developing programmed cellular immunotherapies for cancer and immune disorders, competing with Mesoblast in the cell therapy and regenerative medicine market.
CRISPR Therapeutics
CRSP
Mkt Cap4.91B
CRISPR Therapeutics is engaged in gene editing and gene-based medicine, competing with Mesoblast in the broader regenerative medicine and cell therapy sector.
Bluebird bio
BLUE
Mkt Cap98.95M
bluebird bio specializes in gene therapy for severe genetic diseases and cancer, overlapping with Mesoblast's focus on severe inflammatory and cardiovascular diseases.
Vericel
VCEL
Mkt Cap2.16B
Vericel Corporation focuses on autologous cell therapies for the treatment of patients with serious diseases and conditions, directly competing with Mesoblast's therapeutic areas.
NovoCure
NVCR
Mkt Cap2.31B
NovoCure operates in the oncology sector with a novel therapy, competing indirectly with Mesoblast by targeting some of the same diseases but with different therapeutic approaches.
Sangamo Therapeutics
SGMO
Mkt Cap119.17M
Sangamo Therapeutics focuses on genomic medicine, including gene therapy, competing with Mesoblast in the innovative treatment sector for genetic and complex diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap15.32B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, competing with Mesoblast in the broader market for novel therapies.

About

Biotechnology
Health Technology
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Show more...
CEO
Silviu Itescu
Employees
83
Country
AU
ISIN
AU000000MSB8
WKN
000A0DNPW

Listings